It is prescribed for adult men with benign prostatic hyperplasia (BPH), helping reduce prostate size and improve urinary symptoms over time. The treatment is gradual and requires consistent daily use.
Proscar contains finasteride, which lowers the amount of dihydrotestosterone (DHT) in the prostate.
The standard Proscar presentation is a 5 mg finasteride tablet taken by mouth. The usual regimen for BPH is one tablet once daily, with or without food, when prescribed for that purpose.
The dose and frequency depend on the purpose of use and are agreed with a doctor or pharmacist. Proscar for BPH is not taken as an occasional treatment before urination becomes difficult.
A missed dose is not doubled. Take the next scheduled dose as planned unless a prescriber gives different instructions.
Treatment may continue for months or longer when the benefits remain greater than the drawbacks. Finasteride also affects PSA results, so every clinician ordering or interpreting a PSA test should know that the patient is taking Proscar.
Crushing or breaking tablets is inappropriate when a pregnant person could come into contact with the powder. Intact tablets have a protective coating, while damaged tablets may expose the active substance.
Proscar contains finasteride and is available as an oral tablet. Finasteride lowers the amount of dihydrotestosterone (DHT) in the prostate. How much to use and how often it is taken depend on the purpose of use and are agreed with a doctor or pharmacist.
Finasteride reduces DHT production within the prostate. Lower intraprostatic DHT gradually causes the enlarged gland to shrink, which can reduce pressure on the urethra and improve urinary flow. The mechanism is hormonal rather than a direct muscle-relaxing action.
The biochemical pathway is:
The prostate does not shrink immediately. The effect is gradual.
Two forms of 5-alpha-reductase exist in human tissues. Finasteride has a strong effect on the type involved in prostate DHT production. Reduced DHT changes the hormonal stimulation of prostate cells, allowing gradual reduction in glandular tissue.
Clinical trials and regulatory information reviewed by the FDA describe symptom improvement and reduced risks of urinary retention and surgical intervention with long-term finasteride treatment [1].
Proscar is an oral tablet used in urology for adult men with symptomatic benign prostatic hyperplasia. BPH develops when the prostate enlarges around the urethra, narrowing the urinary passage and making bladder emptying more difficult.
Typical lower urinary tract symptoms include a weak stream, difficulty starting urination, increased night-time urination, urgency, and a sensation that the bladder has not emptied completely. Proscar addresses the enlarged prostate itself rather than providing immediate relaxation of the bladder outlet.
The clinical goals are to:
Finasteride is most useful when prostate enlargement contributes substantially to the symptoms. Men with a smaller prostate or symptoms caused mainly by an overactive bladder may receive a different treatment approach.
A doctor may assess urinary symptoms, prostate size, urinary flow, kidney function, and prostate-specific antigen (PSA) before deciding whether Proscar fits the clinical picture. PSA interpretation also changes during treatment, because finasteride lowers the measured PSA concentration.
Poor results often come from misunderstandings about how finasteride works.
One common mistake is measuring success only by the number of night-time bathroom visits. Doctors may also assess flow, urgency, incomplete emptying, infections, retention episodes, and changes in prostate-related risk.
Another is confusing persistence with failure. Proscar requires regular use and clinical review over time, while an alpha-blocker may feel faster because it acts on smooth muscle rather than prostate tissue.
Men with liver disease should tell the prescriber before treatment because finasteride is extensively metabolised in the liver. The clinical decision may depend on the severity of impairment and the patient’s wider medication history.
The MHRA advises awareness of psychiatric and sexual adverse effects associated with finasteride products, including the need for prompt assessment when depression or suicidal thoughts occur [3].
NOT for you if: you are a child, are pregnant or may become pregnant, have an allergy to finasteride, or have unexplained urinary symptoms that have not been assessed.
Finasteride can affect development of the external genitalia in a male fetus. Pregnant women should not handle crushed or broken Proscar tablets. If contact occurs with damaged tablets, washing the affected area promptly is sensible.
Proscar does not replace assessment for prostate cancer, urinary infection, bladder disease, or neurological causes of urinary difficulty. Sudden inability to pass urine is an urgent problem and should not be managed by taking an extra tablet.
The most discussed adverse effects of Proscar involve sexual function. In clinical studies, reduced libido, erectile difficulty, and ejaculation problems occurred in a small proportion of men and were reported more often with finasteride than with placebo. Breast tenderness or enlargement was less frequent but clinically relevant.
Commonly reported reactions include:
The FDA prescribing information reports that sexual adverse effects were generally uncommon in trials, although the patient experience can be significant even when the numerical frequency is low [2]. Some men notice symptoms early, while others report them after a longer period of treatment.
Persistent sexual symptoms have been reported after discontinuation. The cause and frequency of persistent symptoms remain subjects of medical discussion, so continuing or stopping treatment should be considered individually rather than based on a single online account.
Mood changes also require attention. Depression, anxiety, and suicidal thoughts have been reported with finasteride products. A new or worsening change in mood deserves prompt medical assessment.
Seek urgent medical attention for facial or throat swelling, difficulty breathing, severe skin reactions, or rapidly developing breast changes. A breast lump, nipple discharge, or persistent breast pain needs medical investigation rather than simple observation.
Finasteride can reduce PSA by approximately half after sustained treatment. A rising PSA while taking Proscar may therefore deserve careful assessment, even when the result remains within a laboratory reference range.
BPH treatment depends on prostate size, symptom severity, urinary flow, complications, cardiovascular status, and patient preference. The main approaches differ in speed of relief and long-term purpose.
| Approach | Main action and typical role |
|---|---|
| Finasteride | Lowers DHT, gradually reduces prostate volume, and helps reduce progression-related complications |
| Alpha-blocker | Relaxes smooth muscle around the bladder outlet and prostate, often providing faster symptom relief without shrinking the gland |
| BPH surgery | Removes or reshapes obstructing prostate tissue when medicines are unsuitable, insufficient, or complications develop |
An alpha-blocker may be chosen when rapid symptom relief is the priority. It can cause dizziness, low blood pressure, or ejaculation changes, and it does not reduce prostate volume.
Finasteride may be favoured when the prostate is clearly enlarged and the aim includes reducing the chance of acute urinary retention or future surgery. Its disadvantage is the slow onset and the possibility of sexual or mood-related adverse effects.
Combination treatment with a 5-alpha-reductase inhibitor and an alpha-blocker may be considered for selected men with larger prostates and more troublesome symptoms. NICE guidance on male lower urinary tract symptoms supports matching treatment to symptom pattern, prostate findings, and risk of progression [4].
Transurethral resection of the prostate and other procedures can provide more immediate relief from obstruction, but they involve an intervention with procedural risks, recovery time, and possible effects on ejaculation, bleeding, continence, or erectile function. Surgery is considered when medication does not provide enough control, urinary retention occurs, kidney function is threatened, or complications develop.
In clinical practice, doctors usually set expectations before prescribing Proscar: the treatment aims to change the prostate over time, not to provide an immediate urinary opening. A patient whose main complaint is sudden urgency may need evaluation for another cause rather than an automatic increase in finasteride.
Prescribers also monitor the symptom pattern, urinary retention risk, adverse effects, and PSA trend. PSA results need context because finasteride lowers the measured value. A clinician who does not know about Proscar may misinterpret a result.
A practical medical discussion includes sexual function before treatment. This creates a clear baseline and makes later changes easier to assess without relying on memory.
Men who experience worsening depression, suicidal thoughts, breast changes, or severe allergic symptoms should contact a medical service promptly. Treatment decisions should be based on the severity and timing of the reaction.
Store Proscar in a dry place at ordinary room temperature, away from excessive heat, moisture, and direct sunlight. Keep the tablets in a secure container that prevents access by children and avoids contact with damaged tablets. For travel, place the medicine in its labelled dispensing container and keep it with other essential medicines rather than leaving it in a hot vehicle. The MHRA’s medicine-safety advice remains relevant in 2026, especially for protecting pregnant people from contact with broken finasteride tablets. Do not transfer the tablets to an unlabelled container during travel.
Discuss urinary symptoms, previous urinary retention, liver disease, allergies, sexual function, mood history, and all current medicines before treatment. Tell the doctor about planned or recent PSA testing because finasteride changes PSA interpretation. The European Medicines Agency (EMA) safety information from 2024 recognises finasteride as a medicine requiring attention to sexual, psychiatric, and reproductive safety information. A baseline discussion makes later changes easier to identify.
Facial swelling, throat swelling, breathing difficulty, or a severe blistering rash may indicate a serious allergic reaction and require urgent care. Suicidal thoughts, severe depression, or rapidly worsening psychiatric symptoms also need immediate medical attention. A breast lump, nipple discharge, or marked persistent breast pain requires prompt assessment rather than routine follow-up. MHRA safety communications issued in 2017 highlight the need to act on significant psychiatric symptoms associated with finasteride.
Urinary improvement may take several months because finasteride must lower prostate DHT and allow prostate tissue to shrink. Some men notice changes earlier, while others need a longer treatment period before the benefit is clear. The FDA clinical evidence from 2023 for Proscar evaluates outcomes over sustained treatment rather than after isolated doses. Lack of immediate improvement is not a reason to take extra tablets.
Proscar is often used as a long-term treatment when BPH symptoms and prostate enlargement continue to justify it. The duration depends on symptom control, prostate findings, PSA results, adverse effects, and the risk of urinary retention. NICE guidance updated in 2023 supports periodic review of ongoing lower urinary tract treatment rather than automatic continuation without assessment. Long-term use can be appropriate for selected men, provided the prescriber reviews benefit, sexual and mood effects, and urinary status.
Your order will be securely packed and shipped within 24 hours. This is exactly what your package will look like (images of an actual item sent). It has the size and look of a regular private letter (24x11x0.7 cm) and its contents cannot be seen.
The first month felt unchanged, so I was tempted to stop. By the third month, the stream was better and I woke less often. I noticed lower interest in sex, which was uncomfortable but manageable after discussing it with my doctor.
My main issue had been getting started at night. It improved gradually rather than suddenly. I had reduced ejaculate volume and some erectile difficulty, so the result was useful for urination but not completely free of drawbacks.
Proscar was prescribed after repeated urinary symptoms, but it did not make a quick difference. I developed low mood and stopped taking it after speaking to the prescriber. The urinary problem was investigated again instead of simply increasing the dose.
The treatment became part of my routine, and I had fewer severe episodes of poor flow. I still needed regular reviews and PSA interpretation. I had mild breast tenderness early on, which settled, but I reported it rather than ignoring it.
